So far, many breakthroughs have been made in immunotherapy of breast cancer, for instance, the use of monoclonal antibodies specifically recognizing antigens on tumor cells (e.g., HER2) or the development of specific antibodies targeting immune checkpoints (e.g., PD-L1, PD-1, CTLA4). The gene discussed is ERBB2; the disease is breast carcinoma.